EnvoyerImprimer

News

June 5th, 2009

ImmunID: an investment agreement of € 2.4M

ImmunID, a company specializing in immune repertoire diagnosis since 2005, announced on June 5th, 2009, a first investment agreement of €2.4m with three benchmark investors in the innovation field: Vizille Capital Innovation (through its Vizille Capital Innovation and Sudinnova arms), SOFIMAC Partners (through its Technology and Health fund) and CEA Investissement.

This transaction will allow the financing of the company's development and clinical research projects. Based on the initial validations of its technology, ImmunID now has the means at its disposal to increase the development of its first immune "weather forecast platform" as well as its ImmunTraCkeR® and Immun'Ig® diagnostic tests.

 

Complete the press release

ImmunidTechnologies-dé.JPG